Asad Mbbs Shahzad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Asad Mbbs Shahzad has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Aisha Mbbs Farooq
Jiujiang Medical University, Jiujiang, China
1 shared publication - Amer Kamal
University of Jordan, Amman, Jordan
1 shared publication - Chirumamilla Punith Mbbs Chowdary
Guntur Medical College, Guntur, India
1 shared publication - Khushi Mbbs Nayyar
Department of Internal Medicine, Adesh Institute of Medical Sciences and Research, Bathinda, India
1 shared publication - Maham Mbbs Afzal
Fatima Jinnah Medical University, Lahore, Pakistan
1 shared publication - Mehtab Fatima Mbbs Anwar
Dow Medical College, DUHS, Karachi, Pakistan
1 shared publication
Latest Publications
- Open Access
- 7 February 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (3) , 1576-1582
Does anticoagulation therapy improve outcomes in severe heart failure with reduced ejection fraction? A systematic review
Background: Heart failure with reduced ejection fraction (HFrEF) is a growing health concern, with an increased risk of thromboembolic events. Oral anticoagulants (OACs) are commonly used in HFrEF patients with atrial fibrillation, but their role in patients with sinus rhythm is unclear. Objective: To assess the safety and efficacy of OACs in HFrEF patients with sinus rhythm. Methods: A systematic review of seven studies involving 17 051 patients was conducted. Outcomes included mortality, nonfatal myocardial infarction (MI), nonfatal stroke, and hospitalization rates. Results: OACs significantly reduced non-fatal strokes compared to antiplatelets and placebo. A measurable reduction in nonfatal MIs was observed in most studies. However, no conclusive benefit was found regarding all-cause fatality and rehospitalization rates. The benefit of OACs in stroke prevention was counterbalanced by an increased risk of major bleeding episodes. Conclusion: OACs may have a role in reducing nonfatal cardiovascular events in HFrEF patients with sinus rhythm, particularly those with ischemic etiologies or underlying thrombotic states. However, further research is needed to establish their efficacy and safety in this population.
- 7 February 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (3) , 1576-1582
Open AccessDoes anticoagulation therapy improve outcomes in severe heart failure with reduced ejection fraction? A systematic review
Background: Heart failure with reduced ejection fraction (HFrEF) is a growing health concern, with an increased risk of thromboembolic events. Oral anticoagulants (OACs) are commonly used in HFrEF patients with atrial fibrillation, but their role in patients with sinus rhythm is unclear. Objective: To assess the safety and efficacy of OACs in HFrEF patients with sinus rhythm. Methods: A systematic review of seven studies involving 17 051 patients was conducted. Outcomes included mortality, nonfatal myocardial infarction (MI), nonfatal stroke, and hospitalization rates. Results: OACs significantly reduced non-fatal strokes compared to antiplatelets and placebo. A measurable reduction in nonfatal MIs was observed in most studies. However, no conclusive benefit was found regarding all-cause fatality and rehospitalization rates. The benefit of OACs in stroke prevention was counterbalanced by an increased risk of major bleeding episodes. Conclusion: OACs may have a role in reducing nonfatal cardiovascular events in HFrEF patients with sinus rhythm, particularly those with ischemic etiologies or underlying thrombotic states. However, further research is needed to establish their efficacy and safety in this population.